Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 29 July 2015 | By Michael Mezher
In an effort to boost the safety of approved drugs, the European Medicines Agency (EMA) is piloting a new procedure that would allow companies to seek the agency's advice on designing post-authorization safety studies (PASS).
Currently, EMA and its Scientific Advice Working Party (SAWP) offer scientific advice to companies developing medicines.
The advice is primarily intended to help drugmakers design "trials that are scientifically sound and generate robust data." When giving scientific advice, EMA will answer questions given by a drugmaker "in light of the current scientific knowledge, based on documentation provided by the company."
EMA notes that its advice is "prospective in nature" and is meant to advise companies on strategic issues during development, and is not meant to pre-evaluate clinical data.
Once a drug is authorized, companies are required to conduct various types of postmarket surveillance to ensure their product's safety once on the market.
One way this is done is by conducting PASS. These studies are either non-imposed, meaning a company undertakes the study of its own volition, or imposed. An imposed PASS is usually carried out when a product is authorized to meet an urgent need before more thorough clinical studies can be completed, or by request of the Pharmacovigilance Risk Assessment Committee (PRAC).
Beginning July 2015, EMA is expanding its scientific advice procedure to include scientific advice for designing PASS.
Both SAWP and PRAC will be involved in the pilot, and all advice will be endorsed by PRAC before being issued.
EMA says the pilot will primarily focus on non-imposed PASS, and expects the advice will help companies design higher quality safety studies that will "provide useful information on a medicine in a real-life setting."
EMA says companies participating in the pilot can benefit from:
"a strengthened PRAC-SAWP interactiona lifecycle approach to medicines advice with integrated advice on all aspects of medicines development from involved Committeessupport for proactive pharmacovigilance planningadvice at an early or late stage of the protocol developmenttargeted advice on key issuesa well-defined procedural timetablea pre-submission interaction with Agency secretariat to consider suitability and validity of the dossiera face to face meeting with involved regulators during the procedureengagement with patient representativesoptions to include other stakeholders such as HTAs or FDA further supporting optimised evidence generationthe possibility of seeking follow-up advice"
The pilot is entirely voluntary and will run for one year. EMA has also updated its questions and answers guide for scientific advice to reflect the pilot and has published a letter of intent for companies wishing to participate in the pilot to complete.
EMA, PASS Q&A (Question 10)
Tags: Post-authorization safety studies, PASS, SAWP, PRAC
Regulatory Focus newsletters
All the biggest regulatory news and happenings.